SCHEMBL866533

SCHEMBL866533

Nc1ncnc2c(C3OC(COS(N)(=O)=O)C(O)C3O)cnn12

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ATG7 O95352 20/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL866579 1.00 ATG7 (0.55) ATG7
SCHEMBL29325495 0.82 HIF1A (0.48) —
SCHEMBL29323405 0.82 HIF1A (0.48) —
SCHEMBL16715133 0.82 HIF1A (0.48) —
SCHEMBL3301022 0.82 HIF1A (0.48) —
SCHEMBL25495855 0.82 HIF1A (0.48) —
SCHEMBL20434908 0.82 HIF1A (0.48) —
SCHEMBL17130296 0.82 HIF1A (0.48) —
SCHEMBL20485764 0.82 HIF1A (0.48) —
SCHEMBL16727957 0.82 HIF1A (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077814-A1 SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES WANG ZHONG (US) 2012-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077814-A1 SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES NEDD8, NAE1, UBA3 ATG7 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback